Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Clinical trial NCT06041776 · RECRUITING

Trial details

NCT number: NCT06041776
Sponsor: Betta Pharmaceuticals Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer EGFR Sensitive Mutation Adjuvant Therapy

Start date: 2023-03-28
Primary completion: 2028-04-30
Enrollment: 570

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.